Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Protara Therapeutics
Biocon Limited
Ain Shams University
VA Office of Research and Development
Peking University
WestVac Biopharma Co., Ltd.
Washington University School of Medicine
Coherence Neuro Australia Pty Limited
Rabin Medical Center
University of Alabama at Birmingham
UNC Lineberger Comprehensive Cancer Center
Relmada Therapeutics, Inc.
Drexel University
Duke University
Abramson Cancer Center at Penn Medicine
Baptist Health South Florida
University of Gaziantep
University of Chicago
Inrobics Social Robotics, S.L.
Zhongnan Hospital
M.D. Anderson Cancer Center
University Health Network, Toronto
M.D. Anderson Cancer Center
Massachusetts General Hospital
Brigham and Women's Hospital
The First Hospital of Jilin University
GlaxoSmithKline
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
Rutgers, The State University of New Jersey
Rigshospitalet, Denmark
University of Miami
National and Kapodistrian University of Athens
Yale University
Rigshospitalet, Denmark
University of Arizona
McMaster University
Centre Hospitalier Universitaire de Liege
University Hospital, Lille
AbbVie
University of Utah
Sun Yat-sen University
TNC Nutrición Terapéutica S.L.
University of Arizona
University Hospital, Ghent
University Hospital, Brest
Centre Leon Berard
University of Rochester
Ottawa Hospital Research Institute